Med24
overweight-obesity 22. 9. 2025 • 2 min read • Europe PMC

SULT-Mediated Lipid Sulfation and the LXR/SREBP-1c Axis: Defining a Sulfur Flux Subtype of Treatment-Resistant Obesity/Adiposity-Based Chronic Disease (ABCD)

Treatment-resistant obesity/adiposity-based chronic disease (ABCD), affecting approximately 20-30% of cases, poses a significant challenge beyond traditional insulin resistance, often manifesting with preserved insulin sensitivity in early stages. This review driven hypothesis proposes that SULT-mediated lipid...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Treatment-resistant obesity/adiposity-based chronic disease (ABCD) affects approximately 20-30% of cases, presenting challenges beyond insulin resistance. This review proposes that SULT-mediated lipid sulfation, facilitated by enzymes SULT1A1, SULT1E1, and SULT2B1, drives this phenotype through activation of the LXR/SREBP-1c axis.

Key Clinical Findings

Upregulated SULTs catalyze PAPS-dependent sulfation of sterols and fatty acids, producing cholesterol sulfate which acts as an LXRα agonist. This process amplifies SREBP-1c expression, increasing the synthesis of FASN and ACACA, resulting in approximately 40% enhanced triglyceride production. Simultaneously, sulfated lipids stabilize perilipins, repelling ATGL and HSL to reduce non-esterified fatty acid release by approximately 50%. Mitochondrial integration impairs CPT1 and ETFDH, attenuating β-oxidation by approximately 30%.

Sponsored content

Mechanistic Insights

Endocrine perturbations, including T3/T4 sulfation, diminish DIO2 affinity and lower basal metabolic rate, synergizing with intact insulin signaling to maintain depot stability. This differs from conventional ABCD, which involves reversible TAG cycling and IRS desensitization. Supporting evidence includes SULT1A1 knockouts conferring approximately 10-15% weight reduction and UCP1 elevation, SULT2B1 inhibition preventing high-fat diet-induced ABCD via enhanced energy expenditure, and human lipidomics showing elevated cholesterol sulfate correlating with BMI. MHO phenotypes, with preserved glucose tolerance despite high adiposity, highlight the novelty, as do high-starch diet models exhibiting ABCD without glucose intolerance. Plasma cholesterol sulfate emerges as a diagnostic biomarker for stratifying resistant cases. Novel sulfur-based interventions, including sulfatase activators, taurine, molybdenum, thiol antioxidants, and steroid desulfators, modulate lipid sulfation pathways to enhance β-oxidation, mobilize non-esterified fatty acids, suppress adipogenesis, and restore endocrine balance.

Original Scientific Source
Europe PMC
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement